All
More highlights from MauiDerm 2014
January 29th 2014New drugs, data and guidelines on acne and rosacea treatment were among the takeaways from days two and three of MauiDerm 2014. Presenters also described evidence-based suggestions for managing pigmentary disorders and updated information on infectious diseases.
Digital skin lesion analysis may help dermatologists classify skin lesions
January 29th 2014A multispectral digital skin lesion analysis device may be useful in helping clinicians to classify clinically ambiguous lesions, detect early melanomas in young adults, and identify outlier lesions that should be biopsied, according to a collection of posters presented at MauiDerm 2014.
Questionnaires measure quality-of-life impact of carcinomas
January 21st 2014In an effort to learn more about patients’ experiences with advanced basal cell carcinoma and basal cell carcinoma nevus syndrome, researchers have developed two new questionnaires to evaluate and assess the effects of the diseases.
FDA approves combo treatment for melanoma
January 14th 2014The Food and Drug Administration has approved GlaxoSmithKline’s Mekinist (trametinib) for use in combination with Tafinlar (dabrafenib) as a possible treatment for patients suffering from inoperable melanoma and certain types of metastatic melanoma.
Next generation technologies promise to enhance treatment of disease
January 1st 2014The implementation of next generation technologies coupled with the acquisition of a more in-depth knowledge of dermatologic diseases and conditions are proving to be very helpful in better treating and managing patients.
A clinician’s opinion on ineffective dermatologic therapies
January 1st 2014Over the decades, many highly useful treatment modalities have been developed which have greatly improved the lives of our patients. However, many additional therapies with questionable usefulness have also become part of our treatment armamentarium.
Secukinumab shows superiority to etanercept
January 1st 2014Recent head-to-head clinical trial results with secukinumab (Novartis) and etanercept (Enbrel, Amgen) show a significant superiority of secukinumab in the treatment and management of patients with moderate-to-severe plaque psoriasis, perhaps heralding a new standard of care for this patient population.
SCC staging update defines high-risk tumors
January 1st 2014A new tumor staging system for cutaneous squamous cell carcinoma (CSCC) has recently been put forward that, according to one recent study, improves prognostic discrimination by more precisely defining the small subset of tumors with a high risk of metastatic and death.
Initial accurate diagnosis critical for rare tumors
January 1st 2014Atypical fibroxanthoma (AFX) and undifferentiated pleomorphic sarcoma (UPS) share a similar histological picture. But unlike AFX, UPS can have an aggressive clinical course, underscoring the importance of initial accurate diagnosis of these tumors, and the implementation of appropriate therapy.